XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Other Income
 6 Months Ended
Mar. 31, 2020
Component of Operating Income [Abstract]  
Other Income
Note 3Other Income

 

Grant Income

 

During the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was being received in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.

 

The grant income has been deferred when received and amortized to other income as the related research and development expenditures are incurred. During the three and six months ended March 31, 2020, the Company recognized $74,944 and $149,888, respectively (2019:$74,527 and $149,055, respectively) of this grant on its statement of operations within grant income.

 

Research and development incentive income

 

The Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit (“NYC Biotech credit”), and the Australian research and development tax incentive credit (the “Australia R&D credit”) through a program administered through the Australian Tax Office (the “ATO”), which provides for a cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company’s wholly owned subsidiary, Anavex Australia Pty Ltd. (“Anavex Australia”). Research and development incentive income during the three and six months ended March 31, 2020 and 2019 represents the receipt by the Company’s Australian subsidiary, of the Australian research and development incentive credit, (the “ATO R&D Credit”), as well as receipt by the Company of the New York City Biotechnology Credit (“NYC Biotech credit”).

 

During the three and six months ended March 31, 2020, the Company recorded research and development incentive income of $717,328 (AUD 1,203,000) and $1,660,543 (AUD 2,548,000), respectively (2019: $510,990 and $924,672, respectively) in respect of the ATO R&D Credit for eligible research and development expenses incurred during the period.

 

During the three and six months ended March 31, 2019, the Company recorded research and development incentive income of $250,000 and $250,000 respectively, in respect of the NYC Biotech credit.